Concepedia

Rajiv Patni

RP

Statistics

Publications

9

Citations

683

H-Index

9

Active since

1999

Affiliations

Adamas Pharmaceuticals (United States)(Current)

University of Kansas Medical Center

Parkinson's Research and Education Foundation

University of Toledo

University of Miami

Rajiv Patni is an author at Adamas Pharmaceuticals (United States) specializing in pharmacotherapy, clinical pharmacology, and pharmacology.

Publications per year

1999–2019

9

Publications

9

Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes

Murray Epstein, Gordon H. Williams, Myron H. Weinberger et al. · Clinical Journal of the American Society of Nephrology · 2006 · 456 citations

, , +15

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

Lawrence Elmer, Jorge L. Juncos, Carlos Singer et al. · CNS Drugs · 2018 · 62 citations · Full text

, , +16

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia

Robert A. Hauser, Rajesh Pahwa, William A. Wargin et al. · Clinical Pharmacokinetics · 2018 · 44 citations · Full text

, , +17

Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure

M. B. Patel, Ilya V. Kaplan, Rajiv Patni et al. · Circulation · 1999 · 35 citations · Full text

, , +15

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials

Rajesh Pahwa, Stuart Isaacson, Joohi Jimenez‐Shahed et al. · Parkinsonism & Related Disorders · 2018 · 28 citations · Full text

, , +16

1–5 of 9